Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ERAS

SILVERARC CAPITAL MANAGEMENT, LLC position in ERAS

ERASCA INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 1,330,455 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$19.5M, representing 2.49% of its reported portfolio and ranking #13 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ERAS holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)1.33M sh
Reported value held$19.50M
Portfolio Weight2.49%
First reportedQ1 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's ERAS position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ERAS in Q1 2024 at 223,845 shares (US$461K). The position peaked in Q1 2026 at 1,851,812 shares, worth US$30.0M. Across 11 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,330,455 shares valued at US$19.5M — an increase of 67,429 shares quarter over quarter.. Notable position changes include a 3392% increase in Q2 2024 (shares rose 16% over the following quarter), a 65% trim in Q2 2025 (shares rose 72% over the following quarter), a 47% trim in Q3 2025 (shares rose 71% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 223.84K $461.12K New
Q2 2024 7.82M $18.45M Add
Q3 2024 6.95M $18.96M Reduce
Q4 2024 7.54M $18.94M Add
Q1 2025 7.37M $10.09M Reduce
Q2 2025 2.57M $3.26M Reduce
Q3 2025 1.37M $2.98M Reduce
Q4 2025 1.32M $4.90M Reduce
Q1 2026 1.85M $29.96M Add
Q2 2026 1.26M $23.14M Reduce
Q3 2026 1.33M $19.50M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ERAS and 13F data

ERAS (ERASCA INC) is a Health Care company. 75 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ERAS

All ERAS fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held ERAS?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ERAS holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ERAS?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 1.33M shares of ERAS (ERASCA INC), valued at $19.50M, representing 2.49% of its reported portfolio and ranking #13.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ERAS?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in ERAS. The position peaked in Q1 2026 at 1.85M shares.

Which other funds hold ERAS?

Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 75 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.